Joo I, et al. - The diagnostic performance of MDCT in analyzing tumor resectability in patients with borderline resectable pancreatic cancers after receiving neoadjuvant chemoradiation therapy (CRT) compared with patients undergoing upfront surgery was determined. It was shown that neoadjuvant CRT did not notably decrease the performance of MDCT for the prediction of local resectability in patients with borderline resectable pancreatic cancers. Taking into account post-CRT changes, such as non-progression in tumor-vascular contact, MDCT could offer better sensitivity for locally resectable disease.